Abstract

Background: Diabetes mellitus is one of the biggest health catastrophes in the world. Its management depends on the patient's lifestyle and the physician’s experience. Outcomes with oral antidiabetic drugs (OADs) alone are suboptimal. As disease progresses and cell function deteriorates, insulin initiation may be necessary for glycaemic control. Thus, the purpose of this study was to assess the ‘Implication of Insulin Therapy Initiation (Jusline®) in Type II Diabetes Mellitus Patients who fail to achieve Euglycemia with Oral Antidiabetic Drugs’. Methods: This is a prospective, open label, single arm study. Patients with type II diabetes with HbA1c > 8%, on OADs for more than 6 months, with minimum 3 months of double complementary synergistic OADs were recruited. Insulin dose was individualized to achieve glycemic control as defined by the ADA. Results: 51 patients (20M/31F) with ages ranging from 32-80 years were enrolled. Majority (42.9%) were on Metformin HCl & Glyburide therapy before enrollment. Out of the 51 patients, 33.3% were on single night dose of average 13 + 4.8 units of Insulin-N. HbA1c dropped significantly from 10.5 + 2.1 to 7.9 + 1.2 (p<0.0001); its percent change ranged between 0.8% to 65% with an average of 23.7% + 14.0 and a median of 19.7%; after 84 days. Conclusion: Euglycemia was achieved in 29.4% of patients with no serious side effects. Therefore, initiation of insulin therapy should not be delayed in primary care practice as it facilitates stringent glycemic control and offers promise to change the pharmacological treatment of type II diabetes mellitus.

Authors and Affiliations